- Home
- SNDX vs XPRO Comparison
SNDX vs XPRO Comparison
Compare SNDX & XPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNDX
- XPRO
- Stock Information
- Founded
- SNDX 2005
- XPRO 1938
- Country
- SNDX United States
- XPRO United States
- Employees
- SNDX N/A
- XPRO N/A
- Industry
- SNDX Biotechnology: Pharmaceutical Preparations
- XPRO Oilfield Services/Equipment
- Sector
- SNDX Health Care
- XPRO Energy
- Exchange
- SNDX Nasdaq
- XPRO Nasdaq
- Market Cap
- SNDX 1.1B
- XPRO 1.1B
- IPO Year
- SNDX 2016
- XPRO 2013
- Fundamental
- Price
- SNDX $9.48
- XPRO $9.18
- Analyst Decision
- SNDX Strong Buy
- XPRO Buy
- Analyst Count
- SNDX 11
- XPRO 3
- Target Price
- SNDX $35.91
- XPRO $12.00
- AVG Volume (30 Days)
- SNDX 1.8M
- XPRO 1.1M
- Earning Date
- SNDX 07-31-2025
- XPRO 07-24-2025
- Dividend Yield
- SNDX N/A
- XPRO N/A
- EPS Growth
- SNDX N/A
- XPRO N/A
- EPS
- SNDX N/A
- XPRO 0.58
- Revenue
- SNDX $43,722,000.00
- XPRO $1,720,185,000.00
- Revenue This Year
- SNDX $426.77
- XPRO N/A
- Revenue Next Year
- SNDX $98.31
- XPRO $4.25
- P/E Ratio
- SNDX N/A
- XPRO $15.83
- Revenue Growth
- SNDX N/A
- XPRO 10.48
- 52 Week Low
- SNDX $8.58
- XPRO $6.70
- 52 Week High
- SNDX $25.07
- XPRO $24.50
- Technical
- Relative Strength Index (RSI)
- SNDX 36.85
- XPRO 54.61
- Support Level
- SNDX $11.00
- XPRO $9.24
- Resistance Level
- SNDX $11.83
- XPRO $9.87
- Average True Range (ATR)
- SNDX 0.58
- XPRO 0.43
- MACD
- SNDX -0.11
- XPRO 0.06
- Stochastic Oscillator
- SNDX 10.31
- XPRO 61.88
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
About XPRO Expro Group Holdings N.V.
Expro Group Holdings NV offers products and services that span the well life cycle, including well construction, well flow management, well intervention and integrity, and subsea well access. It maintains operations around the world and specializes in offshore production solutions. It also provides production optimization for both onshore and offshore applications. The company has four operating segments: North and Latin America (NLA); Europe and Sub-Saharan Africa (ESSA); Middle East and North Africa (MENA), and Asia-Pacific (APAC). The majority of its revenue is derived from North and Latin America (NLA) segment.